PDF(Pubmed)
Abstract：
Aim: The main purpose of the present study was to investigate the labor market affiliation of ALK+ NSCLC patients in long-term treatment as well as overall survival and incidence/prevalence. Materials & methods: Nationwide retrospective study of all patients with ALK+ NSCLC in Denmark diagnosed between 2012 and 2018. Results: During the study period ALK+ NSCLC patients had a median overall survival of 44.0 months and a 7.8-fold increase in disease prevalence. Six months prior to diagnosis, 81% of ALK+ NSCLC patients ≤60 years of age were employed. At the end of the 18-month follow-up period, 36% were employed. Conclusion: ALK+ NSCLC patients have prolonged survival following diagnosis, but a large fraction of patients lose affiliation with the labor market.
The purpose of this study was to examine the employment status and survival of patients with ALK+ NSCLC who are undergoing long-term treatment. The researchers conducted a study analyzing data from all such patients diagnosed between 2012 and 2018 in Denmark. The results showed that ALK+ NSCLC patients had a median overall survival of 44.0 months and a that the number of patients increased almost eightfold during the study period. Prior to diagnosis, 81% of ALK+ NSCLC patients who were 60 years of age or younger were employed. However, at the end of the 18-month follow-up period, only 36% of these patients were still employed. In conclusion, ALK+ NSCLC patients tend to have prolonged survival after diagnosis. However, a considerable proportion of these patients lose their affiliation with the labor market, indicating the impact of the disease on employment status.
ALK+ NSCLC patients have prolonged survival following diagnosis, but a large fraction of patients lose affiliation with the labor market following diagnosis. #alkpositive #lcsm.
The purpose of this study was to examine the employment status and survival of patients with ALK+ NSCLC who are undergoing long-term treatment. The researchers conducted a study analyzing data from all such patients diagnosed between 2012 and 2018 in Denmark. The results showed that ALK+ NSCLC patients had a median overall survival of 44.0 months and a that the number of patients increased almost eightfold during the study period. Prior to diagnosis, 81% of ALK+ NSCLC patients who were 60 years of age or younger were employed. However, at the end of the 18-month follow-up period, only 36% of these patients were still employed. In conclusion, ALK+ NSCLC patients tend to have prolonged survival after diagnosis. However, a considerable proportion of these patients lose their affiliation with the labor market, indicating the impact of the disease on employment status.
ALK+ NSCLC patients have prolonged survival following diagnosis, but a large fraction of patients lose affiliation with the labor market following diagnosis. #alkpositive #lcsm.
摘要：
目的：本研究的主要目的是调查长期治疗的ALKNSCLC患者的劳动力市场隶属关系以及总体生存率和发病率/患病率。材料与方法：2012年至2018年在丹麦诊断的所有ALK+NSCLC患者的全国回顾性研究。结果：在研究期间，ALK+NSCLC患者的中位总生存期为44.0个月，患病率增加7.8倍。诊断前六个月,81%的ALK+NSCLC患者≤60岁。在18个月的随访期结束时，36%的人被雇用。结论:ALK+NSCLC患者诊断后生存期延长,但是很大一部分患者失去了与劳动力市场的联系。
本研究的目的是检查接受长期治疗的ALK+NSCLC患者的就业状况和生存率。研究人员进行了一项研究，分析了2012年至2018年在丹麦诊断出的所有此类患者的数据。结果显示，ALK+NSCLC患者的中位总生存期为44.0个月，患者数量在研究期间增加了近8倍。在诊断之前，60岁或以下的ALK+NSCLC患者中有81%被雇用。然而,在18个月的随访期结束时，这些患者中只有36%仍在就业.总之,ALK+NSCLC患者在诊断后往往具有延长的生存期。然而,这些患者中有相当一部分失去了与劳动力市场的联系，表明该疾病对就业状况的影响。
ALK+NSCLC患者诊断后生存期延长，但是很大一部分患者在诊断后失去了与劳动力市场的联系。#alkpositive#lcsm.
本研究的目的是检查接受长期治疗的ALK+NSCLC患者的就业状况和生存率。研究人员进行了一项研究，分析了2012年至2018年在丹麦诊断出的所有此类患者的数据。结果显示，ALK+NSCLC患者的中位总生存期为44.0个月，患者数量在研究期间增加了近8倍。在诊断之前，60岁或以下的ALK+NSCLC患者中有81%被雇用。然而,在18个月的随访期结束时，这些患者中只有36%仍在就业.总之,ALK+NSCLC患者在诊断后往往具有延长的生存期。然而,这些患者中有相当一部分失去了与劳动力市场的联系，表明该疾病对就业状况的影响。
ALK+NSCLC患者诊断后生存期延长，但是很大一部分患者在诊断后失去了与劳动力市场的联系。#alkpositive#lcsm.
